Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States.
Rory Michael ShallisRong WangJan Philipp BewersdorfAmer M ZeidanAmy J DavidoffScott F HuntingtonNikolai A PodoltsevXiaomei MaPublished in: Therapeutic advances in hematology (2021)
As expected, our findings highlight the frequent use of imatinib as the treatment option for older CML patients despite the availability of second-generation TKIs.